NONOF News and Press, Novo-Nordisk A/S From 10/18/23

2023-10-18 08:30:00 ET Summary Mawer Investment Management is a privately owned, independent investment firm, managing over $67B in assets for individual and institutional investors across all major asset classes. This quarter there was a divergence in the performance of holdings ...

2023-10-17 12:08:30 ET More on Johnson & Johnson Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy Johnson & Johnson Q3 Earnings Preview: Don't Count On Different Proposition Post Kenvue Spin-Out Johnson & Johnson: The Bull Case Can...

2023-10-16 02:53:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The tech-focused rally...

2023-10-13 07:25:00 ET Summary Consumer staples stocks, including legendary dividend stocks like Hormel Foods Corporation and Kellanova (formerly Kellogg), have crashed between 20% to 30%. The media has attributed the decline in consumer staples to factors such as weight loss drug...

2023-10-06 23:40:19 ET More on Novo Nordisk Novo Nordisk: DCF Analysis Suggests Significant Undervaluation Novo Nordisk: Catching The Falling Knife Now Could Really Hurt Novo Nordisk: What The Stock Split Means For Traders And Investors Walmart says Ozempic, ...

2023-10-06 18:09:48 ET Summary The biotechnology and pharmaceutical sectors have been under pressure in 2023, with the Invesco Pharmaceuticals ETF down 9% and the iShares Biotechnology ETF down 6%. Elevated interest rates and potential pricing power erosion are the primary headwin...

2023-10-06 13:09:10 ET More on Eli Lilly Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase Eli Lilly POINTs Toward Radiopharmaceutical Ambitions Eli Lilly: Don't Be Fooled By Greed Walmart says Ozempic, weight loss drugs impacting sales - Bloombe...

2023-10-02 14:55:14 ET More on Bristol-Myers, Merck, etc. Bristol-Myers: Out Of Favor (Rating Upgrade) Bristol-Myers Squibb: How Cheap Is Cheap Enough? Bristol-Myers Squibb Looks Grossly Overvalued With LOE Taking A Bite Out Of Topline Merck, Bristol Myers, A...

2023-10-02 12:59:17 ET More on Novo Novo Nordisk: DCF Analysis Suggests Significant Undervaluation Novo Nordisk: Catching The Falling Knife Now Could Really Hurt Novo Nordisk: What The Stock Split Means For Traders And Investors Novo Nordisk underperforms as ...

2023-10-01 12:00:03 ET More on Novo Nordisk Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss Novo Nordisk: DCF Analysis Suggests Significant Undervaluation Novo Nordisk: Catching The Falling Knife Now Could Really Hurt Viatris a...